Drugs / TAR-200
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03404791 | Nov 2017 → Dec 2019 | urinary bladder neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04640623 | Dec 2020 → Jul 2025 overdue | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06211764 | Apr 2024 → Nov 2030 expected | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05714202 | Mar 2023 → Sep 2029 expected | urinary bladder cancer | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04658862 | Dec 2020 → Dec 2026 expected | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06877676 | — | urinary bladder neoplasm | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAR-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03404791 ↗ |
| Modality | Other / unclassified | “TAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder.” PMID 40737582 ↗ Jul 2025 |
| Route | Other | “receive the TAR-200 transuretherally” NCT03404791 ↗ |